ReviewBioengineering (Basel, Switzerland)2023
Advances in Mesenchymal Stem Cell Therapy for Osteoarthritis: From Preclinical and Clinical Perspectives.
Review in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Protective properties of extracellular vesicles in sepsis models: a systematic review and meta-analysis of preclinical studies.Journal of translational medicine · 2023Pooled it
- The role and mechanisms of mesenchymal stem cells in postoperative cognitive dysfunction via immune network regulation.Stem cell research & therapy · 2026Review
- Article
- Safety evaluation of repeated intra-articular injections of human adipose-derived mesenchymal stem cells iniScience · 2026Article
- Adipose-Derived Stromal Cells for the Treatment of Knee Osteoarthritis: A Retrospective Study of Clinical Outcomes and Predictive Factors.Healthcare (Basel, Switzerland) · 2026Article
- Accelerated cartilage regeneration via chondrocyte metabolic reprogramming using nano-steroid-conjugated mesenchymal stem cells in osteoarthritis.Theranostics · 2026Article
- Efficacy of Stromal Vascular Fraction Treatment for Knee Osteoarthritis: A Single-Arm Experimental Trial.Biomedicines · 2025Article
- The Therapeutic Scope of Orofacial Mesenchymal Stem Cells.Bioengineering (Basel, Switzerland) · 2025Review
- Breaking Down Osteoarthritis: Exploring Inflammatory and Mechanical Signaling Pathways.Life (Basel, Switzerland) · 2025Review
- Evaluation of the Safety and Regenerative Potential of Human Mesenchymal Stem Cells and Their Extracellular Vesicles in a Transgenic Pig Model of Cartilage-Bone Injury In Vivo - Preclinical Study.Stem cell reviews and reports · 2025Article
- Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases.Immunity, inflammation and disease · 2025Review
- Cathepsin K Inhibitors as Potential Drugs for the Treatment of Osteoarthritis.International journal of molecular sciences · 2025Review
- Gold Nanoparticles as a Tool to Detect Biomarkers in Osteoarthritis: New Insights.Indian journal of microbiology · 2025Article
- Cell culture expansion media choice affects secretory, protective and immuno-modulatory features of adipose mesenchymal stromal cell-derived secretomes for orthopaedic applications.Regenerative therapy · 2025Article
- Ferroptosis in osteoarthritis: metabolic reprogramming, immunometabolic crosstalk, and targeted intervention strategies.Frontiers in immunology · 2025Review
- Equine adipose-derived stem cells modulateFrontiers in veterinary science · 2025Article
- MRI monitoring of USPIO-labeled BMSCs combined with alginate scaffold for cartilage defect repair.Frontiers in bioengineering and biotechnology · 2025Article
- Stem Cell Exosomes for Osteoarthritis in Veterinary Medicine.Stem cells international · 2025Review
- Combination Hyaluronic Acid and Multipotent Stromal Cells Fails to Improve Rat Knee OA Outcomes Compared to Cells Alone.Orthopedic research and reviews · 2025Article
- Understanding the impact of diabetes on bone health: A clinical review.Metabolism open · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The prevalence of osteoarthritis (OA), a degenerative disorder of joints, has substantially increased in recent years. Its key pathogenic hallmarks include articular cartilage destruction, synovium inflammation, and bone remodeling. However, treatment outcomes are unsatisfactory. Until recently, common therapy methods, such as analgesic and anti-inflammatory treatments, were aimed to treat symptoms that cannot be radically cured. Mesenchymal stem cells (MSCs), i.e., mesoderm non-hematopoietic cells separated from bone marrow, adipose tissue, umbilical cord blood, etc., have been intensively explored as an emerging technique for the treatment of OA over the last few decades. According to existing research, MSCs may limit cartilage degradation in OA by interfering with cellular immunity and secreting a number of active chemicals. This study aimed to examine the potential mechanism of MSCs in the treatment of OA and conduct a thorough review of both preclinical and clinical data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.